Rosetta Genomics and the American Ambion signed a licensing deal

The agreement gives Ambion access to the Rosetta Genomics database, which includes RNA sequences for a variety of applications in the field of medical research

Rosetta Genomics Ltd., a private Israeli biotechnology company that develops diagnostic and pharmaceutical products based on unique microRNA genes, and the American company Ambion, which specializes in developing technologies for RNA gene research, announced the signing of a cooperation agreement The agreement gives Ambion access to microRNA sequences discovered by Rosetta Genomics and currently in process. Patent approval. The agreement allows Ambion to adapt the RNA-type gene platform under development for the detection, quantification and characterization of microRNA sequences discovered by Rosetta Genomics. The products produced in this process will enable the development of basic and applied research initiatives among researchers in academia and industry around the world.

There is now growing evidence that microRNA genes appear in different concentrations in healthy cells compared to diseased cells. Therefore, measuring and changing microRNA levels may be potential tools in the diagnosis and treatment of many diseases.

"The identification and understanding of the role of microRNA genes in human health constitutes a new frontier in the field of medical research and diagnostics," said Matt Winkler, CEO of Ambion. "We are pleased that the agreement with Rosetta Genomics will allow us to expand our product line to the researchers who specialize in the field of microRNA and who can use these research products to more deeply examine the roles of microRNA in biological processes such as neurological development, reaction of The immune system, viral infections and oncogenesis".

"MicroRNAs appear to play a vital role in the way genes are expressed and controlled," said Amir Avniel, president of Rosetta Genomics. "Because of this, it is likely that microRNA will play a central role in the diagnosis and treatment of many diseases. Our partnership with Ambion will make it possible to apply Rosetta Genomics' technology and the database it owns in research initiatives, with a significant impact on the healthcare field in the coming years."

About microRNAMicroRNA genes are a group of small RNA molecules that were recently discovered to be essential for development and growth in humans, animals and plants. MicroRNAs are important regulators of gene expression, and it is likely that they will play a very important role as indicators of various disease states. Recent evidence indicates that microRNAs play an essential role in the development of cancer and viral infections.

Leave a Reply

Email will not be published. Required fields are marked *

This site uses Akismet to filter spam comments. More details about how the information from your response will be processed.